Leerink Partnrs Estimates Zymeworks’ Q1 Earnings (NYSE:ZYME)
Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Zymeworks in a research note issued to investors on ...
Modern Healthcare21h
Top digital health funding: Proscia, Click Therapeutics, Inspiren
Proscia sells digital pathology software and artificial intelligence tools to pharmaceutical companies and diagnostic ...
Aura Biosciences, Inc. (NASDAQ:AURA) Sees Large Decrease in Short Interest
Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) saw a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 1,120,000 ...
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
Additional approximately $21 million tied to data release for the Company’s BEST1 programRESEARCH TRIANGLE PARK, N.C., March ...
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX
Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic ...
Le Lézard18h
Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
Pulmatrix, Inc. ("Pulmatrix" or the "Company") , a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and ...
Pulmatrix Inc.: Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets
Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets ...